The Corona Remedies IPO is gaining strong traction among investors. Despite being a 100% Offer For Sale (OFS) issue, the IPO has received significant attention, especially because its Grey Market Premium (GMP) is rising rapidly. This indicates strong listing-day expectations. In this blog, we break down everything you need to know — GMP, price band, lot size, company details, risks, strengths, and expert views — in simple, clear English.
Corona Remedies IPO Overview
Company: Corona Remedies Ltd Sector: Pharmaceuticals & Healthcare IPO Type: 100% OFS (Offer For Sale) Issue Size: ₹655.37 crore Listing On: NSE & BSE Since this IPO is a complete OFS, the company itself won’t receive any fresh capital. The funds go to selling shareholders — important for long-term investors to note.
IPO Price Band IPO Dates Lot Size
The company has set its price band at: ₹1,008 – ₹1,062 per share Retail Lot Size: 14 shares Minimum Investment: approx ₹14,868 This makes it easily accessible for retail investors. IPO Opens: 8 December 2025 IPO Closes: 10 December 2025 Allotment Date: 11–12 December 2025 (tentative) Expected Listing Date: 15 December 2025
Corona Remedies IPO GMP (Grey Market
The GMP for Corona Remedies is showing strong momentum. GMP Range: ₹300 – ₹365 per share If GMP stays in this zone, the estimated listing price could be: ₹1,062 (upper band) + ₹365 = approx ₹1,425 per share This reflects high interest in the unofficial marketorona Remedies IPO has captured market attention due to its strong GMP and positive sentiment. It appears promising for investors seeking listing gains, while long-term investors should carefully evaluate valuations and business fundamentals.
DIGI MERCH STORE PRINT ON DEMAND
Company Strengths
Corona Remedies is a fast-growing Pharma company with several business advantages Strong Domestic Market Presence Its products have high brand recognition in multiple states. Diversified Product Portfolio Operations across key therapeutic areas like Gastro Cardio Antibiotics Dermatology Consistent Revenue Growth Year-on-year financials show steady growth. Improving Profit Margins Better operational efficiency is aiding profitability.
You Must Consider Before Investing.
100% OFS Structure No fresh funds will enter the company Long-term growth will rely solely on internal performance High Dependence on Domestic Market A few key brands contribute significantly to revenue Sector Competition Generic pharma is highly competitive, affecting pricing power
Expert View — Should You Apply?
For Listing Gains (Short-Term Traders) Yes The strong GMP makes it attractive for possible listing-day profits, if allotment is received. For Long-Term Investors Proceed with caution. OFS means no fund infusion for future expansion Valuations appear premium Long-term returns depend on consistent performance
CoronaRemediesIPOGMP. Affiliatemarketing
CoronaRemediesIPOnews. Instagramposts
CoronaRemediesIPOreview. Facebookposts
CoronaRemediesIPOdemand. Partyinvitations
CoronaRemediesIPOvaluation TechTips
Comment
